Parkinson’s disease is progressive, and current treatment methods cannot prevent the disease from progress, and the diagnosis requires life-long medication, but the longer the drug is administered, the shorter the drug effects, especially oral drugs, the resulting series of needles, adhesive drug development and application.
What are the new drugs for Parkinson’s treatment?
1 Kim Yoonping (injected with Robin Golding): On 21 June 2024, it was approved by the National Drug Control Authority of China for the treatment of Parkinson’s disease, the world’s first long-lived slow-release microball formulation for Parkinson’s disease. The development of a microball platform based on green leaf pharmaceuticals, which allows for a weekly delivery of drugs, reduces symptoms fluctuations and adverse reactions due to fluctuations in drug concentrations, and helps to increase patient dependence and facilitate long-term management of the disease.
Rottoline: This drug is a dopamine receptor agonist that can be effective in improving the static tremors, motion reduction and muscle proficient symptoms of early Parkinson patients, and is also very useful for late-stage Parkinson patients, and can be used in conjunction with Medoba or other monomethane inhibitors.
3. Parkinson ‘ s new drugs, which may be subsequently listed in the R & D process in the country.
(i) safenamide
Essentially, on 27 April 2022, a request for NDA (Application for a new drug) was made in the country, which is the new type of drug imported for the treatment of Parkinson, to be approved in the first paragraph of the country. The safenamide is a selective inhibitor for MAOB (single oxidation enzymes B), and clinical studies have found that it is possible to significantly extend the “opening” period and reduce the “closed” period. The drug was approved by the United States FDA in 2017 and became the first new chemical entity to be approved in the United States for the treatment of Parkinson disease in over a decade.
The mechanism of action, safenamide, is a new chemical entity with a unique mode of action, including selective and reversible MAO-B inhibition and disruption of voltage-dependent sodium circuits, thus regulating unusual avalamides releases. MAO-B degrades dopamine, and dopamine is important for a fluid autonomous movement, and saphamine is expected to avoid degradation of dopamine from MAO-B, thus reducing the mobility of Parkinson patients during their shutdown period.
Clinical trials have shown that safenamide can control motor symptoms and motor complications for Parkinson patients in the short term and can sustain the treatment for two years, with a significant extension of the start period and a shorter closure period. In addition, the sports function indicators for patients during the start-up period were better rated and there was no uncontrolled movement.
Opicarpen
The NDA application for basic information in Opikapen was accepted on 10 March 2021, but was not granted as of August 2023. Researched by the Bial Pharmaceutical Institute and subsequently authorized for the development of Japanese Ono Pharmaceuticals for the treatment of Parkinson’s Disease, which was approved in Germany in 2016 and in the United States in 2020.
For Parkinson’s patients, new drugs, special effects, etc. offer more options and hope. Treatment cannot be blind or simply seek new drugs. The choice of medicines that are more appropriate to their condition, under the guidance of a specialist, regular visits, moderate exercise, maintenance of good living patterns and hobbies for physical and mental health are powerful weapons against Parkinson ‘ s disease.
